Hydroxyurea vs placebo: All‐cause mortality
- Population
- people with sickle cell disease
- Intervention
- Hydroxyurea
- Comparison
- placebo
- Outcome
- All‐cause mortality
Reviews word the same question differently. Two decision models (TypeSafe's Jev and Liquid AI's d1) judged each wording of the population, intervention, comparator and outcome against the others, and rows count as this question only when both agree on all four. Timing, setting and subgroup never split a question: they are shown on each row.
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
How each review answered it
Current versions only| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hydroxyurea vs placebo All‐cause mortality · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | 1 study · 193 participants | Low |
Summary of findings ‐ Hydroxyurea vs placebo Death during the study (all deaths) · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | RR 0.65 [0.19, 2.27] | 5 studies · 784 participants | Moderate |
Summary of findings ‐ Hydroxyurea vs placebo Death during the study (all deaths) · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2017) · Cochraneearlier version CD002202.PUB2, superseded | RR 0.39 [0.08, 1.96] | 4 studies · 577 participants | Moderate |
Trials and studies behind the answers
The primary studies that full-text reviews tie to these outcomes. Reviews from the Summary of Findings tier list no included studies here, and trials have not yet been matched to questions on their own, so this list is incomplete.